Daiichi teams up with GAIA for cholesterol DTx in Europe Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.

#DaiichiSankyo's European division has signed a partnership with German #digitalhealth company #GAIA to sell a #digitaltherapeutic (DTx) designed to support people with high #cholesterol levels.

#BoehringerIngelheim and #ClickTherapeutics have revealed the data from their pivotal trial of #digitaltherapeutic (DTx) CT-155 for #schizophrenia, which has shown efficacy against some of the symptoms that are hardest to address with drug therapies.

pharmaphorum.com/news/boehrin...